COSM Nasdaq Wholesale-Drugs, Proprietaries & Druggists' Sundries Financials FY2016βFY2025
Cosmos Health Inc. had $65.3M of revenue in fiscal 2025, up 19.9% on the year before. Over five years, revenue changed +3.3% a year on average.
Last close Β· Oct 23, 2026
$0.26
3.2%Hi! I read Cosmos Health Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+19.9%
Yes. Sales grew 19.9% last year.
Does it make a profit?
β29.3%
No. It lost money last year.
Does profit turn into cash?
β13.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Cosmos Health Inc. had $65.3M of revenue in fiscal 2025, up 19.9% on the year before. Over five years, revenue changed +3.3% a year on average. Its operating margin was β25.6%, up 3.0Β pts: of every 100 in sales, about β26 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Cosmos Health Inc. lost $19.1M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$8.5M in fiscal 2025, β13.0% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $1.7M of shares on the open market and sold none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$1.7M
2 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 349,825 | $0.20 | $0.1M | Form 4 |
| Jul 29, 2026 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 766,284 | $0.18 | $0.1M | Form 4 |
| Jun 16, 2026 | Georgios TerzisChief Financial Officer | Bought | 168,135 | $0.25 | $0.0M | Form 4 |
| Jun 11, 2026 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 218,447 | $0.21 | $0.0M | Form 4 |
| Jun 10, 2026 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 701,447 | $0.23 | $0.2M | Form 4 |
| Feb 12, 2026 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 388,532 | $0.37 | $0.1M | Form 4 |
| Feb 11, 2026 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 291,262 | $0.41 | $0.1M | Form 4 |
| Jan 23, 2026 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 90,325 | $0.50 | $0.0M | Form 4 |
| Jan 20, 2026 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 353,321 | $0.50 | $0.2M | Form 4 |
| Jan 14, 2026 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 493,495 | $0.45 | $0.2M | Form 4 |
| Jan 12, 2026 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 113,185 | $0.50 | $0.1M | Form 4 |
| Jan 8, 2026 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 156,190 | $0.52 | $0.1M | Form 4 |
| Jan 7, 2026 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 124,880 | $0.52 | $0.1M | Form 4 |
| Jan 6, 2026 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 133,953 | $0.54 | $0.1M | Form 4 |
| Dec 19, 2025 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 88,314 | $0.49 | $0.0M | Form 4 |
| Dec 15, 2025 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 168,472 | $0.42 | $0.1M | Form 4 |
| Nov 28, 2025 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 76,360 | $0.64 | $0.0M | Form 4 |
| Nov 25, 2025 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 55,732 | $0.63 | $0.0M | Form 4 |
| Nov 21, 2025 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 56,080 | $0.68 | $0.0M | Form 4 |
| Nov 20, 2025 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 51,315 | $0.62 | $0.0M | Form 4 |
| Nov 19, 2025 | Grigorios SiokasChief Executive Officer, Director, 10% owner | Bought | 61,614 | $0.65 | $0.0M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Cosmos Health Inc. owes $3.0M more than it holds in cash.
Cash, debt and the ratios that show how comfortably Cosmos Health Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $0.3M | $20.8M | $3.9M | $0.3M | $0.8M |
| Debt incl. finance leases | $17.9M | $5.0M | $6.5M | $4.1M | $3.8M |
| Debt / equity | 4.1x | 0.1x | 0.2x | 0.2x | 0.2x |
| Interest coverage | β1.6x | β3.2x | β25.2x | β15.4x | β8.8x |
| Current ratio | 1.3x | 2.6x | 1.5x | 1.0x | 1.0x |
| Quick ratio | 1.2x | 2.4x | 1.3x | 0.8x | 0.9x |
| Total assets | $49.4M | $68.0M | $66.0M | $54.3M | $65.5M |
| Total liabilities | $45.0M | $28.4M | $30.0M | $29.8M | $47.1M |
| Shareholders' equity | $4.4M | $39.3M | $36.0M | $24.5M | $18.4M |
| Net debt (β = net cash) | $17.6M | β$15.7M | $2.7M | $3.8M | $3.0M |
KIRA Β· Its return on capital was β61.6%: every 100 invested in the business earned about β62 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Cosmos Health Inc. passes 5 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 3 / 8 | 4 / 9 | 4 / 9 | 4 / 9 | 2 / 9 | 2 / 9 | 3 / 9 | 5 / 9 |
| Accruals ratio | 48.9% | 37.0% | β47.8% | 6.7% | 36.4% | β1.9% | 1.8% | β4.3% | β14.1% | β17.9% |
| Altman Z'' | β6.56 | β8.08 | β4.35 | β4.91 | β0.10 | β1.46 | 0.88 | β4.26 | β7.94 | β7.92 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $6.8M | $30.0M | $37.1M | $39.7M | $55.4M | $56.2M | $50.3M | $53.4M | $54.4M | $65.3M |
| Noninterest expense | $0.0M | $0.9M | β$5.8M | $0.3M | $0.0M | β | $0.2M | β | β | β |
| Gross profit | $0.6M | $2.0M | $2.4M | $3.7M | $8.1M | $8.3M | $6.0M | $4.3M | $4.3M | $7.9M |
| Research and development | β | β | β | β | β | β | β | $0.2M | $0.5M | $0.5M |
| Operating income | β$0.2M | β$4.9M | β$1.2M | β$0.3M | $2.7M | β$4.5M | β$7.5M | β$21.8M | β$15.5M | β$16.7M |
| Interest expense | $0.2M | $0.7M | β$1.0M | β$1.4M | $2.8M | $2.8M | $2.3M | $0.9M | $1.0M | $1.9M |
| Pretax income | β$0.6M | β$6.2M | β$9.0M | β$3.1M | $1.2M | β$7.8M | β$13.1M | β$18.5M | β$16.2M | β$19.1M |
| Income tax | $0.0M | $0.0M | β$0.0M | $0.2M | β$0.4M | $0.1M | β$0.8M | $0.0M | $0.0M | $0.0M |
| Net income | β$0.6M | β$6.2M | β$9.1M | β$3.3M | $0.8M | β$8.0M | β$13.8M | β$18.5M | β$16.2M | β$19.1M |
| Net income to common | β | β | β | β | β | β | β$63.9M | β$25.8M | β$22.4M | β |
| Diluted EPS | $80,741.00 | β$0.49 | β$0.68 | β$0.25 | $0.06 | β$23.74 | β$33.16 | β$2.15 | β$1.17 | β$0.63 |
| Diluted shares | 0.13B | 0.01B | 0.01B | 0.01B | 0.01B | 0.00B | 0.00B | 0.01B | 0.02B | 0.03B |
| Cash flow | ||||||||||
| Cash from operations | β$2.1M | β$8.8M | β$1.6M | β$4.8M | β$11.5M | β$7.1M | β$14.9M | β$15.6M | β$7.7M | β$8.4M |
| Capital expenditure | $0.0M | $0.1M | $0.5M | β | $0.1M | $0.6M | $0.1M | $1.3M | $0.4M | $0.1M |
| Free cash flow | β$2.1M | β$8.8M | β$2.1M | β | β$11.6M | β$7.7M | β$14.9M | β$16.9M | β$8.1M | β$8.5M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.4M | $0.4M | $0.4M | $0.1M | $0.6M | $1.2M | $1.4M |
| Stock-based compensation | $0.0M | $0.3M | $0.2M | β | β | $5.9M | $0.0M | $0.6M | $1.7M | $2.3M |
| Share buybacks | β | β | β | β | $0.2M | $0.4M | β | $0.1M | $0.0M | β |
| Dividends and buybacks | β | β | β | β | $0.2M | $0.4M | β | $0.1M | $0.0M | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.7M | $0.8M | $3.6M | $0.3M | $0.9M | $0.3M | $20.8M | $3.9M | $0.3M | $0.8M |
| Total debt | β | β | $0.1M | $0.0M | $10.8M | $17.9M | $5.0M | $6.5M | $4.1M | $3.8M |
| Current assets | $2.6M | $9.5M | $18.3M | $21.2M | $40.8M | $39.8M | $56.4M | $36.6M | $25.5M | $38.4M |
| Current liabilities | $4.9M | $13.7M | $22.3M | $28.2M | $34.3M | $29.9M | $21.7M | $24.3M | $25.8M | $38.3M |
| Inventory | β | β | $3.2M | $3.5M | $3.3M | $3.1M | $3.5M | $4.8M | $4.4M | $5.8M |
| Property and equipment, net | $0.1M | $0.1M | $1.4M | $1.7M | $1.8M | $1.9M | $1.8M | $10.3M | $9.7M | $10.6M |
| Goodwill | β | $1.9M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Intangible assets | β | β | $0.2M | $0.2M | $0.2M | $0.4M | $0.7M | $7.8M | $7.7M | $7.5M |
| Total assets | $3.1M | $10.7M | $20.7M | $23.9M | $43.8M | $49.4M | $68.0M | $66.0M | $54.3M | $65.5M |
| Total liabilities | $4.9M | $13.7M | $24.0M | $30.3M | $48.0M | $45.0M | $28.4M | $30.0M | $29.8M | $47.1M |
| Preferred stock | β | β | β | $0.0M | $0.0M | $0.0M | $0.4M | $0.0M | β | β |
| Shareholders' equity | β$1.8M | β$3.0M | β$3.3M | β$6.5M | β$4.2M | $4.4M | $39.3M | $36.0M | $24.5M | $18.4M |
| Margins | ||||||||||
| Gross margin | 8.9% | 6.5% | 6.5% | 9.2% | 14.5% | 14.8% | 11.8% | 8.1% | 7.9% | 12.1% |
| Operating margin | β3.0% | β16.2% | β3.3% | β0.6% | 4.9% | β8.1% | β14.8% | β40.9% | β28.6% | β25.6% |
| EBITDA margin | β2.9% | β16.2% | β3.2% | 0.3% | 5.6% | β7.4% | β14.6% | β39.7% | β26.3% | β23.5% |
| Net margin | β8.9% | β20.7% | β24.4% | β8.3% | 1.5% | β14.2% | β27.5% | β34.7% | β29.7% | β29.3% |
| FCF margin | β31.7% | β29.4% | β5.6% | β | β21.0% | β13.7% | β29.7% | β31.8% | β14.9% | β13.0% |
| Efficiency ratio | 0.2% | 3.0% | β15.7% | 0.8% | 0.1% | β | 0.4% | β | β | β |
| Returns | ||||||||||
| Return on capital | β | β | β | β | 47.1% | β16.3% | β25.1% | β44.6% | β43.4% | β61.6% |
| Return on capital employed | 11.6% | 160.9% | 77.8% | 5.9% | 28.4% | β23.2% | β16.1% | β52.4% | β54.4% | β61.4% |
| Return on equity | β | β | β | β | β | β7,287.5% | β63.3% | β49.2% | β53.4% | β89.1% |
| Return on assets | β19.3% | β90.0% | β57.8% | β14.8% | 2.4% | β17.1% | β23.5% | β27.7% | β26.9% | β32.0% |
| Return on tangible equity | β | β | β | β | β | β204.5% | β165.8% | β91.3% | β133.4% | β176.4% |
| Growth | ||||||||||
| Revenue growth | β | 344.3% | 23.6% | 7.0% | 39.6% | 1.5% | β10.5% | 6.0% | 2.0% | 19.9% |
| Net income growth | β | β | β | β | β | β1,070.0% | β | β | β | β |
| EPS growth | β | β100.0% | β | β | β | β39,666.7% | β | β | β | β |
| Share count change | β | β89.8% | 4.1% | β0.2% | 0.3% | β95.1% | 193.5% | 520.7% | 60.0% | 58.2% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β | β | β2.0x | 3.2x | β | β | β | β | β |
| Debt / equity | β | β | β | β | β | 4.1x | 0.1x | 0.2x | 0.2x | 0.2x |
| Interest coverage | β1.1x | β6.5x | β | β | 1.0x | β1.6x | β3.2x | β25.2x | β15.4x | β8.8x |
| Current ratio | 0.5x | 0.7x | 0.8x | 0.7x | 1.2x | 1.3x | 2.6x | 1.5x | 1.0x | 1.0x |
| Quick ratio | 0.5x | 0.7x | 0.7x | 0.6x | 1.1x | 1.2x | 2.4x | 1.3x | 0.8x | 0.9x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.2% | 0.2% | 1.4% | β | 0.2% | 1.0% | 0.1% | 2.5% | 0.8% | 0.1% |
| Stock comp / revenue | 0.2% | 1.1% | 0.7% | β | β | 10.5% | 0.0% | 1.1% | 3.1% | 3.5% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 3.0 | 4.0 | 4.0 | 4.0 | 2.0 | 2.0 | 3.0 | 5.0 |
| Altman Z'' | β6.6 | β8.1 | β4.4 | β4.9 | β0.1 | β1.5 | 0.9 | β4.3 | β7.9 | β7.9 |
| Accruals ratio | 48.9% | 37.0% | β47.8% | 6.7% | 36.4% | β1.9% | 1.8% | β4.3% | β14.1% | β17.9% |
Source: SEC EDGAR XBRL filings (CIK 0001474167). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
